VIGL Vigil Neuroscience Inc.: Business Value to Revenue

Public company logo of Vigil Neuroscience Inc. (VIGL)

Vigil Neuroscience (VIGL) relies on partnerships with scientific foundations to accelerate the development of dementia drugs. The business valuation relative to revenue reflects market expectations, where the mark indicates the current valuation level. Price growth depends on the results of phase two trials, although the lack of profit and dependence on external investments create significant risks.

Vigil Neuroscience Inc. (VIGL): Enterprise Value-to-Revenue Ratio from 07/04/2022 to 11/20/2026

Vigil Neuroscience Inc. - analytical breakdowns and key metrics (VIGL)

- current quotes and average value forecast:
Fundamental company valuation:VIGL, Vigil Neuro
Manufactured product of Vigil Neuroscience, Inc.

Investors utilize this ratio for comparative asset analysis, as it benchmarks Enterprise Value against annual revenue, neutralizing the impact of debt on the valuation. The stability of this metric is supported by the security of Vigil Neuroscience (VIGL) operational supply chains for raw materials, which minimizes production risks and is reflected in the EV/Sales ratio trend.

Competitor analysis

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|Business Value to Revenue CPRX|denalitherapeutics.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Harmony Pharma HRMY|BHVN: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - EV/Sales Multiple|Company Value to Revenue Ratio PRAX (Praxis Medicines)|Enterprise Value-to-Revenue Ratio Anavex Life Sciences (AVXL)|Enterprise Value-to-Revenue Ratio CBLL (CeriBell EEG)|EV/Sales Multiple PRTA (Prothena Corp)|alector.com (ALEC) - Enterprise Value-to-Revenue Multiple|ANNX: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Omeros|NGNE: EV/Sales Multiple|Company Value to Revenue AC Immune|Company Value to Revenue VYGR|Company Value to Revenue Ratio NMRA (neumoratx.com)|Company Value to Revenue SCLX (Scilex Holding Company, Inc.)|Enterprise Value-to-Revenue Ratio TVGN (Tevogen Bio)|Enterprise Value-to-Revenue Ratio Alpha Cognition ACOG|CGTX - Company Value to Revenue|IKT - Enterprise Value-to-Revenue Ratio|SAVA: Enterprise Value-to-Revenue Ratio|Assertio Therapeutics (ASRT) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Coya Therapeutics Inc (COYA)|Enterprise Value-to-Revenue Ratio Vistagen|Company Value to Revenue Ratio OVID (ovidrx.com)|Enterprise Value-to-Revenue Ratio Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Enterprise Value-to-Revenue Multiple|Alterity Therapeutics Ltd. - Company Value to Revenue|CLNN - Company Value to Revenue|PEPG - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Enterprise Value-to-Revenue Ratio|ANVS (Annovis Bio, Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio gracetx.com|EV/Sales Multiple Firefly Neuroscience, Inc.|Enterprise Value-to-Revenue Ratio ANEW Medical (KLTO)|NRSN - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple RVPH (Reviva Pharmaceuticals Holdings Inc.)|Enterprise Value-to-Revenue Coefficient MTVA (metaviatx.com)|NeurAxis Inc. - EV/Sales Multiple|Total Company Value-to-Revenue Ratio heliusmedical.com HSDT|PASG: EV/Sales Multiple|Neuphoria - Business Value to Revenue|Company Value to Revenue NERV|ATHA: Business Value to Revenue|Enterprise Value-to-Revenue Ratio Addex Therapeutics Ltd (ADXN)|ALZN (Alzamend Neuro Inc.) - Business Value to Revenue|EV/Sales Multiple CYCN (cyclerion.com)|Enterprise Value-to-Sales Ratio Protagenic|KTTA: Company Value to Revenue|Business Value to Revenue CRGT (cortigent.com)|ATXI: EV/Sales Multiple|BCLI (BrainStorm Cell Therapeutics) - Enterprise Value-to-Revenue Ratio|CARA (Cara Therapeutics Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio CHRO|Company Value to Revenue ELYM (Eliem Therapeutics)|Enterprise Value-to-Revenue Ratio ITCI (Intra-Cellular Therapies Inc.)|EV/Sales Multiple LBPH (Longboard Pharma)|EV/Sales Multiple Marinus Pharmaceuticals Inc MRNS|NKGen Biotech Corp - EV/Sales Multiple|Business Value to Revenue NRBO (NeuroBo Pharma)|SAGE (Sage Therapeutics, Inc) - Company Value to Revenue|Company Value to Revenue Ratio SNPX|Company Value to Revenue TRVN|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE